Lung cancer remains the leading cause of cancer-related death in the United States. The American Cancer Society estimates 238,340 people will be diagnosed with lung cancer in 2023, with non-small cell lung cancer (NSCLC) accounting for the majority of cases (roughly 80% to 85%).The treatment paradigm of antibody-drug conjugates (ADCs) in lung cancer is discussed in this article. Lung cancer is a highly competitive segment, with blockbusters like KEYTRUDA and TAGRISSO claiming as one of its primary indications. Based on the DESTINY-Lung02 study, ENHERTU (trastuzumab deruxtecan) is becoming the standard of care in second-line HER2-mutant NSCLC, with an ORR of 57.7%. In ...
